The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Episodes
Thursday Jul 25, 2019
Thursday Jul 25, 2019
There’s growing interest in cannabinoids for their therapeutic potential in a range of conditions, but one challenge therapeutic developers face is a reliable and consistent supply. Teewinot Life Sciences is using synthetic biology to produce a range of cannabinoids. We spoke to Michael Luther, president and CEO of Teewinot Life Sciences, about the companies process for producing cannabinoids, its business model, and the therapeutic and consumer areas it plans to pursue.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.